Literature DB >> 6635445

In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.

R B Jones, G L Ridgway, S Boulding, K L Hunley.   

Abstract

Rifamycins are highly active against Chlamydia trachomatis, but the possible development of resistance has been of concern. The ability of rifampin, rifamide, and DL473 to induce resistance in chlamydiae and the effect of combinations of antibiotics on chlamydiae were evaluated in tissue culture. When chlamydiae were exposed to stepwise increases in the concentration of rifampin or rifamide, resistance rapidly emerged. Stepwise resistance did not emerge after exposure to DL473, although organisms resistant to one rifamycin were resistant to all three. Single-step emergence of resistance to rifampin or DL473 was also demonstrated. However, these resistant organisms were difficult to maintain in tissue culture. Combinations of ampicillin, erythromycin, or a tetracycline with rifampin or DL473 were neither synergistic nor antagonistic against chlamydiae. However, subinhibitory amounts of erythromycin or oxytetracycline prevented the emergence of resistance to rifampin. Such combinations may prove useful in therapy for chlamydial infections.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635445     DOI: 10.1093/clinids/5.supplement_3.s556

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

1.  Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Authors:  Andrei Kutlin; Stephan Kohlhoff; Patricia Roblin; Margaret R Hammerschlag; Paul Riska
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study.

Authors:  M A Huaman; C T Fiske; T F Jones; J Warkentin; B E Shepherd; L A Ingram; F Maruri; T R Sterling
Journal:  Epidemiol Infect       Date:  2014-08-22       Impact factor: 2.451

3.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 4.  Antimicrobial chemotherapy of chlamydial infection: where next?

Authors:  G L Ridgway
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

5.  Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis.

Authors:  K Wolf; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice.

Authors:  X X Bin; K Wolf; T Schaffner; R Malinverni
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

9.  Isolation and initial characterization of a series of Chlamydia trachomatis isolates selected for hydroxyurea resistance by a stepwise procedure.

Authors:  G Tipples; G McClarty
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

10.  Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis.

Authors:  Ute Dreses-Werringloer; Ingrid Padubrin; Lars Köhler; Alan P Hudson
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.